Clinical trials: Hair Loss
Breast Cancer, Alopecia
Scalp Cooling to Prevent Chemo-induced Hair Loss
Determine that the Orbis Paxman Hair Loss Prevention System is safe and effective in reducing chemotherapy-induced alopecia in woman with breast cancer undergoing neoadjuvant or adjuvant chemotherapy.
- Trial name
- SCALP (NCT01986140)
- Testing
- PAXMAN Orbis Scalp Cooler, Control No treatment
- Where
- 7 sites in United States
- Volunteers
- 236 people
- Sponsor
- Julie Nangia
Alopecia
Clinical Trial in Females With Female Pattern Hair Loss
This is a year-long clinical trial to evaluate the effectiveness and safety in women with Female Pattern Hair Loss (FPHL), comparing a new 5% minoxidil topical foam (MTF) formulation applied once a day versus the 2% minoxidil…
- Trial name
- NCT01145625
- Testing
- 5% Minoxidil, 2% Minoxidil
- Where
- 12 sites in United States, Canada and 3 more
- Volunteers
- 322 people
- Sponsor
- Johnson & Johnson Healthcare Products Division of McNEIL-PPC, Inc.
Androgenetic Alopecia, Coronavirus Disease 2019
Association of Androgenetic Alopecia and Severity of Coronavirus Disease 2019 (COVID-19).
Coronavirus disease 2019 (COVID-19) can cause variable symptoms ranging from mild common cold-like symptoms to severe life threatening pneumonia.
- Conditions
- Androgenetic Alopecia, Coronavirus Disease 2019, Covid19, Male Pattern Baldness
- Trial name
- NCT04898166
- Where
- Pakistan
- Volunteers
- 300 people
- Sponsor
- Syeda Mahanum Ali
Androgenetic Alopecia, Hair Loss
Treatment of Androgenetic Alopecia in Males
The purpose of this study is to evaluate the efficacy of the HairMax LaserComb 2009 7 Beam model in promoting hair growth in males diagnosed with androgenetic alopecia when treatment is applied as directed.
- Conditions
- Androgenetic Alopecia, Hair Loss, Male Pattern Baldness
- Trial name
- NCT00947505
- Testing
- HairMax LaserComb 2009, 7 Beam, HairMax LaserComb
- Where
- 2 sites in United States
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Lexington International, LLC
Lichen Planopilaris, Frontal Fibrosing Alopecia
Oral Low-Dose Naltrexone for Lichen Planopilaris and Frontal Fibrosing Alopecia
Oral naltrexone was initially FDA approved to treat opioid use disorder and alcohol dependence at doses from 50-100mg/day. At lower doses of 1-5mg/day, naltrexone has been used off-label with success in treatment of several…
- Trial name
- NCT04409041
- Testing
- Low-Dose Naltrexone
- Where
- United States
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Frontal Fibrosing Alopecia
A Trial to Assess the Effect of Delgocitinib Cream 20 mg/g on the Molecular Signature, Safety, and Efficacy in Adults With Frontal Fibrosing Alopecia
This purpose of this trial was to investigate the molecular signature of frontal fibrosing alopecia (FFA) and the effect of delgocitinib cream 2% on reversing the FFA disease signature in active lesions.
- Trial name
- NCT05332366
- Testing
- Delgocitinib cream, Delgocitinib cream vehicle
- Where
- United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- LEO Pharma
COVID-19, SARS-CoV2
Anti-Androgen Treatment for COVID-19
This study is intended to explore the possible protective role of anti-androgens in SARS-CoV-2 infection
- Conditions
- COVID-19, SARS-CoV2, Androgenetic Alopecia, Prostate Cancer
- Trial name
- NCT04446429
- Testing
- Proxalutamide, Standard of Care
- Where
- Brazil
- Volunteers
- 268 people
- Sponsor
- Applied Biology, Inc.
Eyelash Hypotrichosis, Alopecia Areata
Safety and Efficacy of Bimatoprost Solution in Treating Eyelash Loss or Hypotrichosis in Children
This study will evaluate the safety and efficacy of bimatoprost solution 0.03% once daily application to the upper eyelid margins compared with vehicle in treating eyelash loss or hypotrichosis (inadequate or not enough…
- Trial name
- NCT01023841
- Testing
- bimatoprost ophthalmic solution 0.03%, Vehicle Sterile Solution
- Where
- 2 sites in United States, Brazil
- Volunteers
- 71 people
- Sponsor
- Allergan
Lichen Planopilaris of Scalp, Alopecia Areata
Mechanical Intervention on the Scalp Microbiome: Setting the Stage for the Future Management of Cicatricial Alopecias
The objective of this study is to assess the effect of standardized scalp care, specifically mechanical cleansing with the Venus Glow™ Device and water, on the scalp microbiome.
- Trial name
- NCT06357169
- Testing
- Venus Glow
- Where
- United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- University of Minnesota
Alopecia, Alopecia, Androgenetic
Safety and Pharmacokinetics Study of New Formulation of Bimatoprost in Patients With Alopecia
This study will investigate the safety, tolerability, and pharmacokinetics of new formulation of bimatoprost following topical application in patients with alopecia.
- Conditions
- Alopecia, Alopecia, Androgenetic, Baldness
- Trial name
- NCT01189279
- Testing
- bimatoprost Formulation A, bimatoprost Formulation B, bimatoprost Formulation C
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Allergan
Alopecia Areata (AA)
A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of IMG-007 in Adult Alopecia Areata Participants
The primary objective of the study is to evaluate the safety of IMG-007 in adults with Alopecia Areata.
- Trial name
- NCT06060977
- Testing
- IMG-007
- Where
- 17 sites in United States, Canada
- Volunteers
- 29 people
- Sponsor
- Inmagene LLC
Polycystic Ovary Syndrome (PCOS)
MLE4901 vs. Placebo for the Treatment of PCOS
This is a Phase 2b double-blind, randomized, parallel-group, placebo-controlled study of MLE4901 versus placebo in women with PCOS.
- Trial name
- NCT02865915
- Testing
- MLE4901
- Where
- 31 sites in United States
- Volunteers
- 55 people
- Sponsor
- Millendo Therapeutics US, Inc.
Alopecia
ATI-501 Oral Suspension Compared to Placebo in Subjects With Alopecia Areata, Alopecia Universalis or Alopecia Totalis
This Phase 2, multicenter, randomized study will evaluate the safety, tolerability and efficacy of ATI-501 for the treatment of Alopecia Areata (AA), Alopecia Universalis (AU) or Alopecia Totalis (AT) in adult subjects.
- Trial name
- NCT03594227
- Testing
- ATI-501 400mg BID (Low dose), ATI-501 600mg BID (Mid dose), ATI-501 800mg BID (High dose)
- Where
- 25 sites in United States
- Volunteers
- 87 people, healthy volunteers welcome
- Sponsor
- Aclaris Therapeutics, Inc.
Androgenetic Alopecia
Computer-Assisted Versus Manual Hair Harvest Comparative Study
The objective of this clinical study is to investigate and compare the safety and efficacy of the Restoration Robotics Computer-Assisted Harvesting System to the manual hair follicle harvesting method following a nine-month…
- Trial name
- NCT00926211
- Testing
- ARTAS™ System, Manual Hair Harvest
- Where
- 2 sites in United States
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Restoration Robotics, Inc.
Alopecia Areata
An Open-Label Single-Arm Clinical Trial to Evaluate The Efficacy of Abatacept in Moderate to Severe Patch Type Alopecia Areata
Alopecia areata (AA) is a common disease of the immune system, known as an "autoimmune" disease. In this disease, the immune system mistakenly destroys the hair follicle, causing hair to fall out.
- Trial name
- NCT02018042
- Testing
- Abatacept
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Columbia University
Keratosis, Actinic
A Study to Evaluate the Safety and Tolerability of Tirbanibulin Ointment 1% in Adult Participants With Actinic Keratosis
The purpose of the study is to evaluate the safety, tolerability and treatment effect of tirbanibulin ointment 1% when applied to a field of approximately 100 cm^2 on the face or balding scalp.
- Trial name
- NCT05279131
- Testing
- Tirbanibulin ointment 1%
- Where
- 7 sites in United States
- Volunteers
- 105 people
- Sponsor
- Almirall, S.A.
Alopecia Areata
Treatment of Alopecia Areata (AA) With Dupilumab in Patients With and Without Atopic Dermatitis (AD)
Alopecia areata is a medical condition, in which the hair falls out in patches. The hair can fall out on the scalp or elsewhere on the face and body.
- Trial name
- NCT03359356
- Testing
- Dupilumab
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Alopecia Areata
Study of DAXDILIMAB for the Treatment of Moderate-to-Severe Alopecia Areata
The purpose of this study is to assess the preliminary efficacy, safety, tolerability, PK, and PD of Daxdilimab in participants with moderate to severe AA, with ≥50% and ≤95% total scalp hair loss as defined by the SALT score at…
- Trial name
- NCT05368103
- Testing
- Daxdilimab
- Where
- 13 sites in United States, Canada
- Volunteers
- 30 people
- Sponsor
- Amgen
Androgenetic Alopecia
A Novel Approach to Treating Androgenetic Alopecia in Females With Low Level Laser Therapy
This study will acquire data on hair growth of the head that is the result of treatment with a non-heat generating, laser product.
- Trial name
- NCT01967277
- Testing
- Handi-Dome Laser, Incandescent red light source.
- Where
- 2 sites in United States
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Capillus, LLC
Androgenetic Alopecia, Hair Loss
Treatment of Androgenic Alopecia in Males
The purpose of this study is to evaluate the change in terminal hair count at 16 and 26 weeks compared to baseline measurements.
- Conditions
- Androgenetic Alopecia, Hair Loss, Male Pattern Baldness
- Trial name
- NCT00947219
- Testing
- HairMax LaserComb, Control device
- Where
- 3 sites in United States
- Volunteers
- 79 people, healthy volunteers welcome
- Sponsor
- Lexington International, LLC